Skip to main content

Radiation Pneumonitis

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Hanlim Pharm
Hanlim PharmKorea - Seoul
1 program
1
HL301 tablet 300mgPhase 21 trial
Active Trials
NCT04632342Unknown87Est. Feb 2022
Genomics
GenomicsUK - Oxford
1 program
PirfenidonePHASE_21 trial
Active Trials
NCT02296281Unknown48

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Hanlim PharmHL301 tablet 300mg
GenomicsPirfenidone

Clinical Trials (2)

Total enrollment: 135 patients across 2 trials

NCT04632342Hanlim PharmHL301 tablet 300mg

Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients

Start: Nov 2020Est. completion: Feb 202287 patients
Phase 2Unknown

Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury

Start: Jan 201548 patients
Phase 2Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.